Trial Profile
Salvage TACE for unresectable HCC: switching the chemotherapeutic agents.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Miriplatin (Primary) ; Epirubicin
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2018 New trial record